A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.

Research output: Contribution to journalArticle

Abstract

A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.

Details

Authors
  • Timo Vesikari
  • Nicholas Brodszki
  • Pierre van Damme
  • Javier Diez-Domingo
  • Giancarlo Icardi
  • Lone Kjeld Petersen
  • Clément Tran
  • Stéphane Thomas
  • Alain Luxembourg
  • Martine Baudin
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Pediatrics
Original languageEnglish
Pages (from-to)992-998
JournalPediatric Infectious Disease Journal
Volume34
Issue number9
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes